- Consolidates to One Single Corporate
Brand Identity -
MISSISSAUGA, ON, Dec. 18, 2020 /CNW/ - Nuvo Pharmaceuticals
Inc. (TSX:NRI) (OTCQX:NRIFF) d/b/a Miravo Healthcare (Miravo or the
Company), a Canadian focused healthcare company with global reach
and a diversified portfolio of commercial products, today announced
that effective immediately it will begin doing business as (d/b/a)
Miravo Healthcare. The Company is not changing its legal name
or those of its wholly owned subsidiaries.
As part of the corporate rebranding, effective January 4,
2021, the Company will trade as "MRV" on the Toronto Stock Exchange
and "MRVFF" on the OTCQX. The Company's website URL has
changed to www.miravohealthcare.com.
"We are excited for the future as Miravo Healthcare," said
Jesse Ledger, Miravo's President and
CEO. "The corporate rebranding reflects Nuvo's evolution into a
growing, multi-asset Company, which was transformed by the
acquisition of the Aralez Pharmaceuticals Canada business at the
end of 2018. Miravo consolidates the Nuvo and Aralez brands
under one common name. As Miravo, we will continue to focus
on expanding our Canadian and international businesses through
organic growth of our core Canadian products - Blexten®,
Cambia®, and Suvexx®, targeted in-licensing
and acquisition opportunities to further build out our product
pipeline and out-licensing of distribution rights for our
proprietary products - Pennsaid® 2%,
Resultz®, Suvexx and Yosprala™."
Mr. Ledger continued, "Miravo is an Italian word meaning "to aim
straight or to set your sights." Miravo also includes
elements of the Nuvo and Aralez names, signifying the two legacy
entities coming together to move forward with a common purpose and
identity."
About Miravo Healthcare
Miravo is a Canadian focused, healthcare company with global
reach and a diversified portfolio of commercial products. The
Company targets several therapeutic areas, including pain, allergy
and dermatology. The Company's strategy is to in-license and
acquire growth-oriented, complementary products for Canadian and
international markets. Miravo's head office is located in
Mississauga, Ontario, Canada, the
international operations are located in Dublin, Ireland and the Company's
manufacturing facility is located in Varennes, Québec, Canada. The
Varennes facility operates in a
Good Manufacturing Practices (GMP) environment respecting the U.S,
Canada and E.U. GMP regulations
and is regularly inspected by Health Canada and the U.S. Food and
Drug Administration. For additional information, please visit
www.miravohealthcare.com.
Forward-Looking Statements
This press release contains "forward-looking information" as
defined under Canadian securities laws (collectively,
"forward-looking statements"). The words "plans", "expects", "does
not expect", "goals", "seek", "strategy", "future", "estimates",
"intends", "anticipates", "does not anticipate", "projected",
"believes" or variations of such words and phrases or statements to
the effect that certain actions, events or results "may", "will",
"could", "would", "should", "might", "likely", "occur", "be
achieved" or "continue" and similar expressions identify
forward-looking statements. In addition, any statements that refer
to expectations, intentions, projections or other characterizations
of future events or circumstances contain forward-looking
statements.
Forward-looking statements are not historical facts but
instead represent management's expectations, estimates and
projections regarding future events or circumstances, including the
anticipated receipt of certain milestone and royalty payments, the
anticipated launch of certain products and the potential impact of
COVID-19. Such forward-looking statements are qualified in their
entirety by the inherent risks, uncertainties and changes in
circumstances surrounding future expectations which are difficult
to predict and many of which are beyond the control of the Company.
Forward-looking statements are necessarily based on a number of
estimates and assumptions that, while considered reasonable by
management of the Company as of the date of this press release, are
inherently subject to significant business, economic and
competitive uncertainties and contingencies and may prove to be
incorrect. Material factors and assumptions used to develop the
forward-looking statements, and material risk factors that could
cause actual results to differ materially from the forward-looking
statements, include but are not limited to, the validity of the
'907 and '285 Patents claims, the outcome of ongoing patent
litigation, the potential impact of COVID-19 on the Company's
operations, business and financial results and other factors, many
of which are beyond the control of Miravo. Additional factors
that could cause Miravo's actual results and financial condition to
differ materially from those indicated in the forward-looking
statements include, among others, the risk factors included in
Miravo's most recent Annual Information Form dated February 24, 2020 under the heading "Risks
Factors", and as described from time to time in the reports and
disclosure documents filed by Miravo with Canadian securities
regulatory agencies and commissions. These and other factors should
be considered carefully and readers should not place undue reliance
on Miravo's forward-looking statements. Forward-looking statements
should not be read as guarantees of future performance or results
and will not necessarily be accurate indications of whether or not
the times at or by which such performance or results will be
achieved.
All forward-looking statements are based only on information
currently available to the Company and are made as of the date of
this press release. Except as expressly required by applicable
Canadian securities law, the Company assumes no obligation to
publicly update or revise any forward-looking statement, whether as
a result of new information, future events or otherwise. All
forward-looking statements in this press release are qualified by
these cautionary statements.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/nuvo-pharmaceuticals-announces-corporate-rebranding-as-miravo-healthcare-301195702.html
SOURCE Nuvo Pharmaceuticals Inc.